Knowledge Base

In which countries can drugs that have granted by the European Commission be marketed?

8 December 2023
2 min read

Once granted by the European Commission, the centralised marketing authorisation is valid in all European Union (EU) Member States, Iceland, Norway and Liechtenstein.European Union (EU) Member States include: Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain and Sweden.

Keep Reading
Back to all blogs →
Rallybio Announces Early Results on Safety and Efficacy for RLYB212 Monoclonal Antibody to Prevent Infant Thrombocytopenia from Phase 1 Study
Latest Hotspot
3 min read
Rallybio Announces Early Results on Safety and Efficacy for RLYB212 Monoclonal Antibody to Prevent Infant Thrombocytopenia from Phase 1 Study
8 December 2023
Rallybio Reveals Initial Multi-Dose Results from Finalized Phase 1 Evaluation on Safety and Drug Dynamics for RLYB212, a Monoclonal Antibody Targeting HPA-1a to Avert Thrombocytopenia in Infants and Newborns.
Read →
Which espects should be mentioned when recording a AE? And what should the investigator do if the AE is serious?
Knowledge Base
2 min read
Which espects should be mentioned when recording a AE? And what should the investigator do if the AE is serious?
8 December 2023
Type of AE: This refers to any unfavorable and unintended sign (including abnormal laboratory findings not meeting the criteria for an AE) that occurs during or after treatment with the test article.
Read →
What are IDH1 inhibitors and how do you quickly get the latest development progress?
Valuable Targets
5 min read
What are IDH1 inhibitors and how do you quickly get the latest development progress?
8 December 2023
IDH1 inhibitors have made great progress in the treatment of acute myeloid leukemia and glioma, but further research is needed to confirm their clinical efficacy in other tumors.
Read →
How to choose a radiolabeled molecule for a radiodiagnostic drug?
Knowledge Base
2 min read
How to choose a radiolabeled molecule for a radiodiagnostic drug?
8 December 2023
The choice of a radiolabeled molecule for a radiopharmaceutical drug depends on several factors, including the target tissue or organ, the specific disease being studied, and the desired properties of the radiotracer.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.